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INTRODUCTION
Somatostatin (SRIH) is a circulating peptide hor-
mone that displays an array of biological actions 
including the inhibition of hormone secretion, 
modulation of neural transmission, and regulation 
of cell growth (F l o r i o  et al., 1999). Two active 
forms have been described: SRIH-28 and SRIH-14. 
SRIH is heterogenously distributed in the central 
and peripheral nervous systems (E p e l b a u m  et 
al., 1995). SRIH-28 and SRIH-14 are also present 
in non-neuronal tissues such as the gastrointestinal 
tract, endocrine pancreas, and thyroid (R e i c h l i n , 
1983); and the adrenals and thymus (G i l l i e s , 
1997). Hypothalamic SRIH is responsible for the 
inhibition of growth hormone (GH), thyrotropin-
stimulating hormone (TSH), and prolactin (PRL), as 
well as for gonadotrophin secretion from the ante-
rior pituitary (M i l o š e v i ć  et al., 2000a, 2000b, 
2003; N e s t o r o v i ć  et al. 2006). Somatostatin also 
inhibits the secretion of several non-pituitary hor-
mones such as insulin, glucagon, gastrin, secretin, 
and aldosterone (A g u i l e r a , 1981; M i l o š e v i ć 
et al., 1997) and possesses potent antiproliferative 
properties (L a m b e r t s  et al., 1991). 
Many lines of evidence indicate that SRIH plays 
an important physiological role in the modulation 
of adrenal mineralocorticoid secretion in mam-
mals (N u s s d o r f e r , 1996). SRIH-14 administered 
intracerebroventricularly (i.c.v.) inhibited growth 
and secretory activity of the adrenal ZG in the adult 
period of life (M i l o š e v i ć  et al., 1996). Besides 
this direct inhibitory effect, SRIH can also act on the 
adrenal cortex through the hypothalamic-pituitary 
(HP) axis (G a n o n g , 1987).
It is known that the neonatal period is a criti-
cal interval during the life cycle when control 
of neuroendocrine regulation is established. The 
hypothalamic-pituitary-adrenal (HPA) axis is char-
acterized by decreased sensitivity in that period, 
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which is known as the stress-hyporesponsive period 
(Yo s h i m u r a  et al., 2002).
The aim of this study was to investigate whether 
multiple subcutaneous neonatal SRIH-14 treatment 
affects the adrenal cortex cells of female rats in the 
peripubertal and adult periods of life.
MATERIAL AND METHODS
Animals
Time-mated pregnant Wistar rats were housed 
individually and maintained in a controlled envi-
ronment (12 h light : 12 h dark; 22 ± 2°C) with food 
(Subotica Veterinarski Zavod, Subotica, Serbia) and 
water freely available. Female pups were injected 
subcutaneously twice a day (8 AM and 8 PM) with 
20 µg of SRIH-14 (S9129, Sigma, St. Louis, Mo., 
USA) per 100 g of body weight for five consecutive 
days (3rd – 7th day of life; neonatal SRIH-14 treat-
ment). The dose regime for SRIH-14 was selected 
according to R e b u f f a t  et al. (1984) and modified 
by administration every 12 h instead of every 8 h. 
Control female pups received the equivalent volume 
of physiological saline on the same schedule. The 
rats were sacrificed at 8 AM in the peripubertal 
(38th day) or adult (80th day) periods of life. Each 
age group comprised five females. The experimen-
tal protocols were approved by the Local Animal 
Care Committee and conformed to the recom-
mendations given in “Guide for the Care and Use 
of Laboratory Animals” (1996, National Academy 
Press, Washington D.C.)
Light microscopy
Left adrenal glands were excised, fixed in Bouin's 
solution, embedded in paraffin and serially cut into 
5 µm thick sections, which were stained with hema-
toxylin-eosin and examined under a light micro-
scope (Opton).
Morphometry
Stage 1. Zonation of the adrenal gland. In order 
to evaluate the volume of the adrenocortical zones, 
every 10th section of the gland was analyzed using 
the M42 multipurpose test system (We i b e l , 1979) 
at 100x magnification. The absolute volume of the 
glands was calculated on the basis of their weight, 
assuming the average specific gravity of the adrenal 
to be 1.039 g cm-3 (S w i n y a r d , 1938).
Stage 2. Size and number of adrenocortical cells. 
The volume densities of both the nuclei and the 
cytoplasm of parenchymal cells were estimated on 
a screen using the M42 multipurpose test system 
(We i b e l , 1979) at 1000x magnification. For each 
adrenal gland, a single paraffin section containing 
the zona medullaris was chosen, and 30 test areas of 
the zona glomerulosa (ZG) and 50 test areas of the 
zona fasciculata (ZF) and zona reticularis (ZR) were 
analyzed. On the basis of earlier karyometric stud-
Fig. 1. Absolute volume of zona glomerulosa (ZG), zona fascic-
ulata (ZF), and zona reticularis (ZR) in peripubertal and adult 
female rats after subcutaneous administration of SRIH-14 neo-
natally. Values are means ± SD (n = 5),*p< 0.05 vs. control.
Fig. 2. Relative volume of zona glomerulosa (ZG), zona fascicu-
lata (ZF), and zona reticularis (ZR) in peripubertal and adult 
female rats after subcutaneous administration of SRIH-14 neo-
natally. Values are means ± SD (n = 5), *p< 0.05 vs. control.
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ies, the shape coefficient β was assumed to be 1.382 
for the ZF and ZR and 1.500 for the ZG. It relates 
Nv (number of cells counted per unit of volume) 
to Na (number of cells counted per mm2) and Vv 
(volume density) and depends on the axial ratio of 
the estimated nuclei. The number of adrenocortical 
cell nuclei per mm3 was calculated according to the 
method of Weibel (1979). Since rat adrenocortical 
cells are mononuclear, the numerical density of the 
nuclei corresponds to the number of cells per mm3.
Table 1. Body weight and absolute and relative adrenal weight of control (C) and female rats in different periods of life after neonatal 
SRIH-14 treatment.
Groups Body weight (g) Absolute adrenal weight (mg)
Relative adrenal weight 
(mg%)
Peripubertal
C 117.4 ± 8.6 10.6 ± 0.9 4.8 ± 0.8
SRIH-14 130.0 ± 0.7 13.4 ± 1.1 10.3 ± 0.9
Adult
C 255.0 ± 20.7 24.8 ± 2.3 11.7 ± 0.7
SRIH-14 232.5 ± 20.5 25.0 ± 2.2 11.1 ± 1.4
All values are given as means ± SD.
Fig. 3. Adrenal cortex of female rats in: A) control peripubertal rats; B) control adult rats; C) peripubertal rats after multiple treat-
ment with SRIH-14; D) adult rats after multiple treatment with SRIH-14 (H&E, objective magnification x 40).
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Digital images were made on a DM RB 
Photomicroscope (Leica, Wetzlar, Germany) with a 
JVC TK 1280E Video Camera (Leica). For image ac-
quisition, the Qwin program (Leica) was used. 
Statistical analyses
The morphometric data for each group were 
averaged and the standard deviation (SD) of the 
mean was calculated. One-way analysis of vari-
ance (ANOVA), followed by the multiple-range 
test of Duncan was used for statistical comparisons 
between the groups. A probability value of 5% or less 
was considered statistically significant.
RESULTS
Body weight and absolute and relative weight 
of the adrenal gland
The data on body weight and absolute and rela-
tive adrenal weights in the control and SRIH-treated 
animals are summarized in Table 1. As can be seen, 
neonatal SRIH-14 treatment did not induce any 
significant changes (p>0.05) in these parameters in 
female rats at either age (Table 1).
Adrenal cortex
All three cortical zones of the adrenal gland 
(ZG, ZF, and ZR) were clearly visible in all examined 
preparations. The absolute and relative volumes of 
the adrenal cortex in SRIH-14-treated groups of rats 
were not significantly (p>0.05) different from those 
in the corresponding controls (Figs. 1 and 2).
Characteristics of the zona glomerulosa
The ZG was arranged in closely packed ovoid 
clusters, with relatively small columnar or pyramidal 
cells. The nuclei were round or oval with an evident 
nucleolus (Fig. 3A, B). The shape of ZG cells in the 
neonatally SRIH-14-treated animals was not sig-
nificantly changed in the peripubertal period, but 
the cytoplasm in these cells was more intensively 
stained than in the corresponding controls (Fig. 3C, 
D). In adult animals, the zona intermedia was clearly 
visible after neonatal treatment with SRIH-14 (Fig. 
4D). This zone consisted of small cells, each with a 
regularly ovoid nucleus and scarce cytoplasm.
Stereological measurements demonstrated that 
subcutaneous administration of SRIH-14 in the neo-
natal period led to a significant decrease (p<0.05) in 
absolute and relative volumes of the ZG in the peri-
Fig. 4. A) Cellular volume (Vc; μm3) of zona glomerulosa (ZG), 
zona fasciculata (ZF) and zona reticularis (ZR) cells; B) Nuclear 
volume (Vn;μm3) of the zona glomerulosa (ZG), zona fascicu-
lata (ZF), and zona reticularis (ZR); C) Total number of cells 
(1X106) in the zona glomerulosa (ZG), zona fasciculata (ZF), 
and zona reticularis (ZR). Values are means ±SD (n = 5/group), 
*p<0.05 vs. control.
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pubertal period, by 11 and 22%, respectively, com-
pared with the corresponding controls (Figs. 1 and 
2). This was due to atrophy of ZG cells, manifested 
as a significant decrease in their volume, the volume 
of their nuclei, and the total number of ZG cells at 
the peripubertal stage when compared to the cor-
responding controls (Fig. 4A, B, C). In the rats sac-
rificed as adults, the absolute and relative volumes 
of the ZG were slightly decreased, by 4 and 12% 
(p>0.05), respectively, after SRIH-14 administra-
tion in comparison with the corresponding controls 
(Figs. 1 and 2). There were no significant differences 
in the volume of ZG cells and their nuclei and their 
total number (p>0.05) between the two groups of 
adult rats (Fig. 4A, B, C).
Characteristics of the zona fasciculata 
and zona reticularis
There were no significant changes in the histo-
logical appearance and stereological parameters of 
the ZF and ZR in peripubertal and adult female rats 
after neonatal SRIH-14 treatment (Figs. 1, 2, 4A, 4B, 
4C).
DISCUSSION
Neonatal SRIH-14 treatment did not affect the 
body weight in either examined age group. These 
results are in accord with S t a r č e v i ć  et al. (2000), 
who reported that intracerebroventricularly (i.c.v.) 
administered SRIH-14 did not inhibit body weight 
gain in female rats. Moreover, the synthetic soma-
tostatin, an octreotide, applied i.c.v. likewise had no 
significant effect on body weight in male and female 
rats (M i l o š e v i ć  et al., 2001a, 2001b). Thus, the 
absolute and relative adrenal weights in peripubertal 
and adult rats treated with SRIH-14 in the neonatal 
period were not significantly different from those 
of the controls. We have also shown previously 
that i.c.v. treatment with either SRIH-14 or SRIH-
28 did not result in significant changes of absolute 
and relative adrenal weights in adult female rats 
(M i l o š e v i ć  et al., 2001a).
However, treatment SRIH-14 in the neonatal 
period had an immediate and prolonged inhibitory 
effect on ZG cells in female rats sacrificed in the 
neonatal and juvenile periods of life (M i l o š e v i ć 
et al., 2006a, 2006b). The present results demon-
strate that neonatally applied SRIH-14 has a pro-
longed inhibitory effect on the volume of ZG cells 
and their nuclei and the total number of these cells 
right up to the peripubertal period. This confirms 
the earlier observations of M a z z o c c h i  et al. 
(1985), R o b b a  et al. (1986), and R e b u f f a t  et al. 
(1994), who showed that SRIH-14 directly inhibited 
growth and functional capacity of the adrenal ZG. 
There are specific SRIH receptors in the rat ZG (O ' 
C a r o l l , 2003; U n g e r  et al., 2004). Moreover, 
K o n g  et al. (1994) showed that the rat adrenal gland 
expresses high levels of SRIH receptor mRNA, while 
P a w l i k o w s k i  et al. (1990) reported a decreased 
basal proliferation rate of ZG cells, probably caused 
by blocked basal tropic action of angiotensin-II 
(A g u i l e r a  et al., 1981). Regulatory mechanisms 
and pathways by which the central somatostatiner-
gic system affects the rat adrenal ZG remain to be 
elucidated. They are realized via the hypothalamic-
pituitary axis and/or through an altered sympathetic 
tone to the chromaffin cells in the adrenal medulla, 
which exerts paracrine control of cortical func-
tion, especially in the ZG (N u s s d o r f e r , 1996; 
E i n e r - J e n s e n  and C a r t e r , 1995; F e l d m a n 
and We i d e n f e l d , 1995).
On the other hand, our experimental data did 
not reveal statistically significant changes in the 
morphometric parameters of ZG, ZF, and ZR cells 
in adult animals neonatally treated with SRIH-14, 
which confirms previous data (M i l o š e v i ć  et al., 
2001a). The appearance of a visible zona intermedia 
in adults after neonatal SRIH-14 treatment probably 
represents increased proliferative activity of these 
cells, allowing recovery of the ZG in adult rats. 
From these results, it can be concluded that 
neonatal application of SRIH-14 inhibits growth of 
the adrenal ZG and its cells only up to the peripu-
bertal period in female rats, while the effect in adult 
females is negligible.
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KOРА НАДБУБРЕЖНЕ ЖЛЕЗДЕ ПЕРИПУБЕРТАЛНИХ И ОДРАСЛИХ ЖЕНКИ ПАЦОВА 
ПОСЛЕ НЕОНАТАЛНОГ ТРЕТМАНА СА SRIH-14
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Жен­ке пацова од 3-7. дан­а старости (н­еон­а-
тал­н­и период) су субкутан­о третиран­е два пута 
дн­евн­о са SRIH-14 у дози од 20 µg н­а 100 г тел­е-
сн­е масе током пет узастопн­их дан­а. Животиње 
су бил­е жртвован­е у перипубертал­н­ом (38. дан­а)   
ил­и одрасл­ом  (80. дан­а) периоду живота. Кон­-
трол­н­е групе су н­а иден­тичан­ н­ачин­ третиран­е 
физиол­ошким раствором. У поређењу са кон­трол­-
н­им вредн­остима третман­ са SRIH-14 је зн­ачајн­о 
смањио (p<0.05) апсол­утн­и (-11%) и рел­ативн­и     
(-22%) вол­умен­ зон­е гл­омерул­озе (ЗГ) у перипу-
бертал­н­их животиња. Укупан­ број и запремин­а 
ћел­ија ZG и њихових једара такође су зн­ачајн­о 
смањен­и (p<0.05) у пацова третиран­их са SRIH-     
14 у перипубертал­н­ом периоду живота у поређе-
њу са кон­трол­н­им жен­кама. У кори н­адбубрежн­е 
жл­езде одрасл­их жен­ки пацова н­ису запажен­е 
(p>0.05) промен­е морфометријских параметрима    
посл­е SRIH-14 третман­а у поређењу са одговара-
јућом кон­трол­ом. На осн­ову добијен­их резул­тата 
можемо закључити да је субкутан­о третирање 
жен­ки пацова у н­еон­атал­н­ом периоду са SRIH-14 
ин­хибирал­о раст зон­е гл­омерул­озе у перипубер-
тал­н­их пацова.
